This is a comparison, not a ranking. We list 15 telehealth providers that prescribe or dispense GLP-1 medications, grouped by how they operate — brand-name only, brand plus compounded, marketplace, or compounded only — and report each one’s own published terms: medications offered, prescriber type, insurance, pricing, and state coverage.
We do not accept payment, referral fees, or free access from any provider listed here. See exactly how that works in How We’re Funded.
Answer a few questions about how you’d rather pay and what kind of care you want. We’ll show you which providers in our directory actually fit — not a ranking, just a shortlist matched to what you told us, with the reasons shown plainly.
Answer at least one question above and your matches will appear here.
We do not accept payment, referral fees, or free access from any provider in this directory — matching is based only on the criteria above, scored against each provider’s own published terms. See How We’re Funded. Browse every provider in the directory instead of a shortlist.
Before any provider was added, we set the criteria we’d compare on — the same discipline we use for every commercial comparison on this site, described in full in our Editorial Policy:
We have not personally used any of these services, so we are not rating quality of care, wait times, or customer service — we report what each provider publishes about itself, cross-checked against independent reporting where we found it, with a date and a source for every field. This list is not exhaustive; it covers providers with a clear public pricing and terms page as of the verification date below.
Compounded semaglutide and tirzepatide became widely available during 2022–2024 while the brand-name versions were on the FDA's drug shortage list, which temporarily let outsourcing facilities compound copies. Semaglutide came off that shortage list in 2025 and tirzepatide in 2024.
On 30 April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the '503B bulks list' — the mechanism that lets large outsourcing facilities compound a drug at scale without an individual prescription in hand. If finalised, this would end large-scale compounded supply from that channel. The proposal's public comment period closed 29 June 2026, and a final decision is still pending as of this writing.
This does not ban compounding outright. Traditional '503A' pharmacies — which compound to fill an individual, patient-specific prescription under state pharmacy board oversight — operate under a separate legal provision and are not directly affected by the 503B proposal. This is why some providers below can still legally offer compounded products even as the bulk-supply channel narrows.
Separately from the shortage rules, Eli Lilly has sued several telehealth companies (see the flags on individual listings below) alleging that some compounded products were marketed deceptively, including undisclosed additives not present in the approved drug. One of those cases (Willow Health) was dismissed in September 2025; the others remained active as of mid-2026. A lawsuit is an allegation, not a finding of fact — but it's a live legal dispute worth knowing about before you buy.
Verified 2026-07-26 against U.S. Food & Drug Administration; MobiHealthNews; Lengea Law.
Amazon's primary-care and pharmacy arm launched a national GLP-1 programme in April 2026, integrating One Medical's telehealth visits with Amazon Pharmacy fulfilment and same-day delivery in thousands of cities.
On compounding: Prescribes FDA-approved brand-name medications only; does not advertise compounded options.
Checked 2026-07-26.
Positions itself as a metabolic-health company rather than a weight-loss service: a structured 12-month programme combining GLP-1 prescribing (billed through insurance) with one-on-one coaching across food, exercise, sleep, and emotional health — priced as a premium annual commitment rather than a low monthly fee.
On compounding: Prescribes branded semaglutide/tirzepatide; does not advertise compounded options.
Checked 2026-07-26.
A consumer telehealth brand that exited compounded semaglutide for new patients following a settlement with Novo Nordisk, and now separates its recurring membership fee from a separate charge for whichever brand-name medication is prescribed.
Hims & Hers previously offered compounded semaglutide and drew public criticism from Novo Nordisk over how it was marketed, before the March 2026 settlement ended that practice for new patients.
Source: Hims & Hers newsroomOn compounding: Settled with Novo Nordisk on 9 March 2026 and exited compounded semaglutide for new patients; now prescribes FDA-approved brand-name products.
Checked 2026-07-26.
A general telehealth primary-care platform (urgent care, mental health, weight management) that layers weight-loss prescribing on top of ordinary insurance-based visits, rather than a single-purpose GLP-1 subscription.
On compounding: States it prescribes FDA-approved brand-name GLP-1 medications only and does not offer compounded versions.
Checked 2026-07-26.
A vertically integrated telehealth company that operates its own affiliated pharmacy and lab-testing network alongside the prescribing service, rather than routing prescriptions to a separate retail pharmacy.
On compounding: Prescribes FDA-approved brand-name medications; does not advertise compounded options.
Checked 2026-07-26.
WeightWatchers' clinical arm (built from its 2023 acquisition of Sequence), pairing GLP-1 prescribing with the company's long-running behavioural weight-loss programme and dietitian support.
On compounding: Prescribes FDA-approved brand-name medications; does not advertise compounded options.
Checked 2026-07-26.
A women's telehealth platform focused specifically on perimenopause and menopause, offering GLP-1 medications (branded and compounded) alongside menopausal hormone therapy rather than as a standalone weight-loss product.
On compounding: Offers both FDA-approved brand-name medications and compounded semaglutide/liraglutide. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
Combines a coaching-and-community membership with a choice of brand-name or compounded GLP-1 medication, and offers a lower-cost initial clinical assessment before committing to ongoing treatment.
On compounding: Offers both FDA-approved brand-name medications and compounded GLP-1s. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
Layers GLP-1 prescribing (including a lower-cost compounded 'microdose' tier) onto Noom's existing psychology-based behaviour-change coaching app, rather than offering medication as a standalone product.
On compounding: Explicitly offers a compounded semaglutide tier ('Microdose GLP-1Rx') alongside brand-name options. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
An open marketplace where independent clinicians set their own cash-pay prices and patients browse and pick a provider directly, rather than a single company's standardised programme — pricing and exact offerings vary by the individual clinician you choose.
On compounding: Because Sesame is a marketplace, whether a specific listing is brand-name or compounded depends on the individual clinician — check each listing rather than assuming for the platform as a whole.
Checked 2026-07-26.
A women's-health telehealth service (a sister platform to Fella Health, run by the same parent company) built around compounded GLP-1 medication, bundled with lab work and coaching in a single programme fee.
Delilah's sister platform Fella Health was named as a defendant in the same April 2025 Eli Lilly litigation described below (Fella Health entry) — the companies share ownership and compounding pharmacy relationships.
Source: MobiHealthNewsOn compounding: Built entirely around compounded medication. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
A men's-health telehealth service built around compounded semaglutide or tirzepatide, bundled with a membership that includes personalised health coaching. Its lowest advertised prices are monthly-equivalent rates on annual prepaid plans, not month-to-month pricing.
Named as a defendant in an April 2025 federal lawsuit filed by Eli Lilly alleging deceptive marketing of compounded tirzepatide/semaglutide products, including undisclosed additives. As of mid-2026 the case remains in active litigation with no final settlement confirmed.
Source: MobiHealthNewsOn compounding: Built entirely around compounded medication. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
A cash-pay telehealth service built specifically around compounded GLP-1 medications rather than brand-name products, at a lower headline price than most brand-name programmes.
Named as a defendant (under its legal entity, Adonis Health, Inc.) in an April 2025 federal lawsuit filed by Eli Lilly alleging deceptive marketing of compounded tirzepatide/semaglutide products, including undisclosed additives. As of mid-2026 the case remains in active litigation with no final settlement confirmed.
Source: MobiHealthNewsOn compounding: Built entirely around compounded medication. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
A cash-pay telehealth service centred on compounded semaglutide, advertising nationwide availability and one of the lower headline prices in the category.
Named as a defendant in an April 2025 federal lawsuit filed by Eli Lilly alleging deceptive marketing of compounded tirzepatide/semaglutide products, including undisclosed additives. As of mid-2026 the case remains in active litigation with no final settlement confirmed.
Source: Eli Lilly litigation coverage (Yahoo Finance / Reuters)On compounding: Built entirely around compounded medication. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
A cash-pay telehealth service built around compounded tirzepatide. Uniquely among the providers Eli Lilly sued in April 2025, Willow Health's case was dismissed in September 2025 — though it separately faced an advertising-standards challenge over its marketing claims.
Was a named defendant in Eli Lilly's April 2025 lawsuit over compounded tirzepatide marketing, but a federal judge dismissed the case against Willow Health in September 2025 after Lilly failed to show patients or physicians had switched away from its branded products because of it.
Source: Lengea Law (legal industry coverage)Separately, following a challenge from Novo Nordisk, the BBB National Programs' National Advertising Division recommended Willow Health modify or discontinue certain health-related claims made about its compounded semaglutide products.
Source: National Advertising Division referral coverageOn compounding: Built entirely around compounded medication. Compounded drugs are not FDA-approved products in their own right; the FDA does not review compounded formulations for safety, effectiveness, or manufacturing quality the way it does an approved drug.
Checked 2026-07-26.
Every provider above requires a genuine medical evaluation before prescribing. We deliberately left out sites that dispense GLP-1 products — compounded or otherwise — without one: no-prescription “research chemical” sellers and international pharmacies operating outside U.S. licensing. Including those, even with a caution label, would put them on a page designed to look trustworthy, which is precisely what our Medical Disclaimer warns against.
We also left out tools like GoodRx that don’t themselves evaluate or prescribe — they’re price-comparison and pharmacy-discount services, a different category from a telehealth provider, and belong in a future guide of their own rather than this directory.
Within the providers we did include, coverage is deliberately broad: brand-name-only services, hybrid brand-plus-compounded platforms, an open marketplace, and cash-pay compounded-only services — including several currently facing litigation or regulatory challenges, clearly labelled rather than omitted. If a legitimate provider is missing, or something here is out of date, tell us at our contact page and we’ll check it.
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.